CurrentUnitedHealthcarePolicy CS064NJ.Q

Intensity-Modulated Radiation Therapy (for New Jersey Only)

Clinical coverage policy for IMRT (radiation oncology) that applies only to members in New Jersey age 19 and older; IMRT for individuals younger than 19 is covered without further review.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (for New Jersey Only)

Policy CodePolicy CS064NJ.Q

Change TypeRevisedadditions and removals

Effective DateMay 1, 2026

Next Review Date

Key ActionProvide comparative IMRT versus non-IMRT treatment plans and supporting documentation (prior doses, OAR constraints, and rationale) with authorization requests when IMRT is requested for indications not explicitly listed or for re-irradiation.

SourceLink

POLICY UPDATE CHANGES

Revised list of conditions for which IMRT for definitive therapy for the primary site is proven and medically necessary (multiple diagnoses added and some phrasing changed for breast cancer and head & neck lists).

Added several primary site indications to the proven/medically necessary IMRT list: unresectable hepatocellular carcinoma; Hodgkin lymphoma; unresectable intrahepatic cholangiocarcinoma; rectal cancer when treatment involves inguinal lymph nodes; limited-stage small cell lung cancer; retroperitoneal/intra-abdominal soft tissue sarcoma; Stage I-II NSCLC undergoing hypofractionated RT up to 10 fractions.

Removed language indicating compensator-based beam modulation is proven and medically necessary when combined with an IMRT indication.

Changed coverage phrasing for hippocampal-avoidance whole brain radiation therapy to 'considered proven and medically necessary' for up to 10 fractions when criteria are met.

Added or clarified medical-record documentation requirements that medical records must fully support medical necessity and may be requested.

Added CPT codes 77407 and 77412 to the applicable codes list.

Removed CPT/HCPCS codes 77385, 77386, G6015, G6016, and G6017 from the applicable codes list.

When CPT code 77412 is reported, documentation must clearly describe circumstances that justify level 3 rather than level 2 treatment delivery.

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

Archived previous policy version CS064NJ.P.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

19+Age threshold where policy criteria apply

2026-05-01Effective date

>20Tumor/indications enumerated as proven/medically necessary

≤10HA-WBRT fraction limit noted

2CPT codes added

5CPT/HCPCS codes removed

Medical Necessity Criteria for IMRT (New Jersey Only)

Proven and Medically Necessary (Definitive Therapy)

IMRT for definitive therapy for the primary site is considered proven and medically necessary for the following conditions:

ANY of the following

Anus/anal canal cancer
Breast cancer — when any of the following are met
- When the left-sided internal mammary nodes are being treated
- Accelerated partial-breast irradiation of up to five fractions
Central nervous system tumors (primary or benign), including brain, brainstem, and spinal cord
Cervical cancer
Endometrial cancer
Esophageal cancer
Head and neck cancers (including lymphoma and solitary plasmacytomas) — when treatment includes these areas
- Pharynx (nasopharynx, oropharynx, hypopharynx)
- Larynx
- Salivary glands
- Oral cavity (includes the tongue)
- Nasal cavity and paranasal sinuses
Hepatocellular carcinoma, unresectable
Intrahepatic cholangiocarcinoma, unresectable
Hodgkin lymphoma
Mediastinal tumors (e.g., lymphomas, thyroid, thymomas, tracheal cancer)
Non-small cell lung cancer (NSCLC) — when any of the following are met
- Stage I to II undergoing hypofractionated radiation therapy up to 10 fractions
- Stage III undergoing chemoradiation therapy
Pancreatic cancer
Prostate cancer
Rectal cancer when treatment involves inguinal lymph nodes
Small cell lung cancer, limited stage
Soft tissue sarcoma, retroperitoneal/intra-abdominal location
Vulvar cancer

Hippocampal-avoidance whole-brain radiation therapy (HA-WBRT)

Considered proven and medically necessary when ALL of the following are met:

ALL of the following

Brain metastasis
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 OR Karnofsky performance status ≥ 70
Either performance status criterion satisfies this node
Prognosis of 4 months or greater>= 4 months
Absence of leptomeningeal disease

Medically Necessary — Exception / Selected cases (IMRT may be considered)

IMRT may be considered medically necessary for indications not listed above when at least one of the following conditions is present (requests evaluated case-by-case):

ANY of the following

Use of clinically appropriate radiation dose and a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity
Must be demonstrated on a comparison of treatment plans for IMRT vs a non-IMRT technique (e.g., 3D conformal) using established normal tissue constraint guidance (RTOG or QUANTEC)
Same or immediately adjacent area has been previously irradiated and dose distribution must be sculpted to avoid exceeding cumulative tolerance dose of nearby normal tissue
Applies to re-irradiation or overlap with prior fields

Unproven and Not Medically Necessary

The following use is considered unproven and not medically necessary due to insufficient evidence of efficacy:

IMRT used in conjunction with proton beam radiation therapy

Guideline-based recommendations summarized (by tumor type)

Recommendations and implementation remarks from cited professional society guidelines and randomized/observational studies for when IMRT/VMAT (and related techniques) are recommended or preferred:

ANY of the following

Breast cancer — PMRT recommended for node-positive (pN+) disease, all pT4, ypN+ after neoadjuvant therapy, and initial cT4 or cN2-3 regardless of pathologic response; treat chest wall/reconstructed breast and regional lymphatics; moderate hypofractionation preferred in non-reconstructed patients; IMRT/VMAT recommended when 3D-CRT cannot meet targets or spare normal tissues; daily image guidance recommended with IMRT/VMAT; DIBH recommended when it lowers heart/lung dose.
Accelerated Partial Breast Irradiation (APBI) — ASTRO selection criteria: suitable generally ≥50 years with Tis/T1 and margins ≥2 mm; DCIS suitable if screen-detected, low–intermediate grade, ≤2.5 cm, margins ≥3 mm; NCCN notes IMRT/VMAT five fractions every other day preferred regimen.
Central Nervous System (gliomas, meningiomas, medulloblastoma) — ASTRO recommends IMRT/VMAT over 3D-CRT to reduce toxicity for WHO grade 4 and for IDH-mutant grade 2/3 tumors near critical OARs; evidence shows IMRT achieves good local control and functional outcomes.

Clinical conclusions and guideline recommendations reported in excerpt

Summarized statements from trials, meta-analyses, and professional society guidelines — these are evidence/guideline positions, not explicit insurer coverage criteria:

ANY of the following

IMRT may reduce irradiated volumes to critical organs (lung, heart) compared with 3D-CRT and may improve overall survival in esophageal cancer vs 3D-CRT, though radiation toxicity rates may not differ.
NCCN: IMRT or proton beam may be used where minimizing dose to heart/lungs is necessary and cannot be achieved with 3D techniques; IMRT is standard in preoperative, definitive, and postoperative settings for esophageal cancers.
STS/ASTRO/ASCO: IMRT preferred when 3D techniques cannot meet OAR dose constraints for thoracic esophageal cancer.
Head & Neck: Multiple RCTs and meta-analyses show IMRT reduces late xerostomia and other toxicities with similar OS and locoregional control compared with 3D-CRT.

Hippocampal-Avoidance Whole-Brain Radiation Therapy (HA-WBRT) with memantine

Clinical evidence and guideline recommendations summarized:

ALL of the following

HA-WBRT plus memantine associated with lower risk of cognitive failure vs WBRT plus memantine (adjusted HR 0.74; p=0.02) in phase 3 RCT (Brown et al., 2020).
Benefit observed in executive function at 4 months and learning/memory at 6 months; no OS or toxicity difference.
Guideline (ASCO/SNO/ASTRO): Offer memantine and hippocampal avoidance to patients receiving WBRT who have no hippocampal lesions and expected survival ≥4 months.
Patients with asymptomatic brain metastases and poor KPS (<=50 or <70 with systemic options) do not derive benefit.
NCCN: HA-WBRT + memantine 30 Gy in 10 fractions preferred for patients with prognosis ≥4 months and no metastases within 5 mm of the hippocampus or leptomeningeal disease.

Intrahepatic Cholangiocarcinoma — dose escalation

Clinical evidence and guideline recommendations summarized:

ALL of the following

Retrospective MD Anderson series (n=79): BED > 80.5 Gy associated with markedly better 3-year OS (73% vs 38%) and local control (78% vs 45%) in unresectable intrahepatic cholangiocarcinoma.
Delivered with 3D-CRT, IMRT, or passive scatter proton; advanced technique and IGRT/breath-hold recommended to safely deliver high BED.
ASTRO guideline: For unresectable IHC, recommend induction chemo followed by consolidation EBRT; IMRT or proton conditionally recommended for dose-escalated regimens depending on location and liver function.
Strength: conditional; evidence: low.
NCCN: RT modalities (3D-CRT, IMRT, SBRT) may be considered irrespective of tumor location; strongly recommends IGRT with advanced techniques and individualize dosing based on liver function and OAR constraints.

Mediastinal lymphomas, Hodgkin lymphoma and mediastinal tumors — role of IMRT/VMAT

Evidence and guideline recommendations:

ANY of the following

Systematic review: IMRT provides equal or superior PTV coverage and reduces high-dose exposure to heart, esophagus, spinal cord vs APPA/3D-CRT but may increase breast dose and low-dose bath (secondary malignancy risk).
Heterogeneous evidence; small sample sizes.
Single-institution analyses (Filippi et al., Besson et al.) show IMRT/VMAT can reduce heart dose and improve acute toxicity profiles in mediastinal lymphoma and mediastinal tumors; IMRT useful especially for large anterior mediastinal PTVs to reduce cardiac and pulmonary dose.
ILROG guideline: Use smaller fields, lower doses, and advanced techniques (IMRT, breath-hold, IGRT, 4D) when they decrease normal tissue exposure without compromising tumor coverage.
NCCN: Advanced techniques (IMRT/VMAT, DIBH, gating, IGRT, PBRT) appropriate in select cases to spare OARs, especially for younger patients with long-term survival expectations.

Thymic epithelial tumors and thymoma/thymic carcinoma — adjuvant RT

Systematic review findings on postoperative RT:

ALL of the following

Systematic review (Falkson et al., 2022): Postoperative RT associated with improved OS in thymic carcinoma and thymoma, particularly in higher risk patients.
NCDB analysis (Jackson et al.): Postoperative RT linked to improved OS, especially in stage IIB–III and positive margins; benefit not significant in stage I–IIA.
NCCN: Minimum CT-based 3D-CRT; advanced modalities (4D-CT, PET/CT sim, IMRT/VMAT, IGRT, motion management, PBRT) appropriate to safely deliver curative treatment; prefer IMRT over 3D-CRT when reducing dose to heart is important.

Thyroid cancer (locally advanced/nonanaplastic) — IMRT

Evidence supports IMRT with or without chemotherapy in select locally advanced thyroid cancers:

ANY of the following

Phase 2 trial (Romesser et al.): IMRT with/without concurrent chemotherapy in locally advanced thyroid cancer showed 2-year locoregional progression rate 15.2% and acceptable toxicity; concurrent doxorubicin reduced locoregional failures but increased acute toxicity.
Small nonrandomized trial.
ATA 2021: Strong recommendations for IMRT in postoperative settings after R0/R1 resection, for R2 or unresectable nonmetastatic disease, and generally preferred modality for unresectable/postoperative thyroid cancer.
NCCN: Advanced EBRT techniques (IMRT with SIB, IGRT) recommended due to precision and OAR sparing.

Non-small cell lung cancer (NSCLC) — IMRT vs 3D-CRT and dose considerations

Multiple secondary analyses and trials inform technique selection and dose effects:

ALL of the following

NRG/RTOG 0617 secondary analyses: IMRT associated with lower heart doses (e.g., heart V40) and lower rates of grade ≥3 pneumonitis vs 3D-CRT; OS and PFS similar between techniques in randomized trial population.
Speirs et al.: Higher heart dose metrics (e.g., heart V50 ≥25%) independently associated with worse OS; heart dose linked to cardiac toxicity.
RTOG 0617 randomized trial: 74 Gy had worse median OS than 60 Gy when given with concurrent chemo (28.7 vs 20.3 months favoring 60 Gy) and higher QOL decline at 3 months in high-dose arm.
Multiple retrospective and propensity-matched analyses report IMRT reduces pulmonary toxicity and may improve locoregional control in certain subgroups vs 3D-CRT.

Pancreatic cancer — IMRT vs 3D-CRT

Evidence on toxicity and coverage:

ALL of the following

Single-center retrospective (Umezawa et al.): IMRT group had lower rates of acute grade ≥2 GI toxicity (9.7% vs 36%) and lower stomach/duodenum dose metrics vs 3D-CRT in CRT with S-1.
Systematic review (Bittner et al.): IMRT associated with lower rates of several acute (nausea/vomiting, diarrhea) and late GI grade ≥3 toxicities vs 3D-CRT; no differences in OS/PFS.
ASTRO 2019: Recommends modulated techniques (IMRT/VMAT) for localized pancreatic cancer (strong).
NCCN: 3D-CRT, IMRT, and SBRT can improve PTV coverage and reduce OAR dose; dosing individualized per organ constraints; no consensus maximum dose for IMRT.

Prostate cancer — IMRT outcomes and QOL

Observational evidence on QOL and long-term outcomes after IMRT:

ANY of the following

Prospective multicenter study (Maggio et al., 2024): QOL worsened at end of RT but largely recovered by 6 months except physical functioning; acute GI/GU toxicity impacted short-term QOL.
Abu-Gheida et al. (10-year outcomes): IMRT with 70 Gy in 28 fractions showed favorable 10-year biochemical relapse-free survival stratified by risk group (low 88%, favorable intermediate 78%, unfavorable intermediate 71%, high 42%) and low long-term grade 3 toxicity.

Applicable Procedure and Billing Codes

IMRT / Treatment planning and delivery CPT codes listedCPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for IMRT, design and construction per IMRT plan
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed
77407	Radiation treatment delivery; Level 2, single-isocenter (e.g., 3D or IMRT), photons, including imaging guidance, when performed
77412	Radiation treatment delivery; Level 3, multiple isocenters with photon therapy or single-isocenter with active motion management, including imaging guidance, when performed
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex

Added/Highlighted Radiation Treatment Delivery CPTCPT

77407	Radiation treatment delivery, intermediate — standard single-isocenter IMRT or VMAT
77412	Radiation treatment delivery, complex — multiple isocenters or single-isocenter with active motion-management; documentation must justify level 3 versus level 2

Removed CPT/HCPCS codesmixed

77385	Removed from applicable codes list
77386	Removed from applicable codes list
G6015	Removed from applicable codes list
G6016	Removed from applicable codes list
G6017	Removed from applicable codes list

Prior Authorization, Documentation & Billing Requirements

Documentation Required

Support comparative plan documentation for exceptions

For exception requests, submit a side-by-side comparison of the proposed IMRT plan and a representative non-IMRT (e.g., 3D conformal) plan demonstrating the expected reduction in normal-tissue dose; the comparison should reference established normal-tissue constraint guidance (RTOG or QUANTEC).

Include dose-volume histogram comparisons showing OAR dose reductions with IMRT vs non-IMRT.
Cite the applicable RTOG or QUANTEC constraints used to demonstrate decreased probability of clinically meaningful normal tissue toxicity.

Documentation Required

Prior radiation history documentation for re-irradiation requests

For re-irradiation or requests that overlap prior fields, document the prior radiation history including prior doses and the rationale that IMRT is required to sculpt dose so cumulative tolerance of nearby normal tissues will not be exceeded.

Provide prior treatment fields and delivered dose distributions.

Numerical & Clinical Thresholds to Apply

Key Thresholds

Hippocampal-avoidance prognosis thresholdPrognosis >= 4 months

Hippocampal maximum dose (reported ranges)Approximately 12.61–17 Gy

Hippocampal exclusion zoneNo metastases within 5 mm of the hippocampus

BED threshold for unresectable intrahepatic cholangiocarcinoma (IHC)> 80.5 Gy BED associated with improved 3-year OS and local control

Heart V50 associationHeart V50 < 25% associated with better 1- and 2-year OS

Prostate pelvic nodal dose recommendation45-52 Gy

Photon energy and typical fields for prostate IMRT

Clinical & Administrative Background

Intensity-modulated radiation therapy (IMRT) is an advanced external beam radiation technique that uses computer-controlled linear accelerators to modulate the intensity of radiation beams across multiple small beamlets so the dose conforms tightly to the three-dimensional shape of the tumor. IMRT enables delivery of higher, tumor-directed doses while minimizing radiation exposure to adjacent normal tissues and critical structures, improving the therapeutic ratio for many anatomic sites.

IMRT is widely used across multiple tumor sites — including central nervous system, head and neck, breast, prostate, gastrointestinal, lung, gynecologic cancers and other locations — because of its ability to sculpt dose to complex target volumes and spare nearby organs at risk. This capability supports both definitive curative-intent treatments and re-irradiation or anatomically challenging cases where avoidance of cumulative normal-tissue dose is important.

IMRT is often delivered in combination with image-guided radiation therapy (IGRT) to verify target localization and account for anatomic changes during treatment, improving accuracy. When indicated, IMRT may be delivered using volumetric techniques such as VMAT to achieve conformal dose distributions with efficient delivery.

Defined Terms

Definitions

Definitive TherapyRadiation treatments for cancer with curative intent.

IMRTIntensity-modulated radiation therapy — advanced external beam technique that modulates beam intensity to conform dose to target while sparing normal tissues.

VMATVolumetric-modulated arc therapy — a form of IMRT delivered in a rotating arc to achieve conformal dose distributions.

3D-CRTThree-dimensional conformal radiation therapy — technique using 3D imaging to shape beams to the target but without intensity modulation.

DIBHDeep inspiration breath hold — respiratory control technique to reduce cardiac and pulmonary dose during thoracic or left-breast irradiation.

PMRTPostmastectomy radiation therapy.

Summary of Policy Changes

2026-05-01revision (material)Latest

Revised the list of proven/medically necessary IMRT indications for definitive therapy — replaced the breast cancer phrasing to 'breast cancer when any of the [listed] criteria are met', modified head & neck treatment area listings (e.g., changed larynx phrasing), added examples to mediastinal tumors including 'thyroid', and added multiple additional primary-site diagnoses (e.g., unresectable hepatocellular carcinoma; Hodgkin lymphoma; unresectable intrahepatic cholangiocarcinoma; rectal cancer involving inguinal nodes; limited-stage SCLC; retroperitoneal/intra-abdominal soft tissue sarcoma; Stage I–II NSCLC with hypofractionation up to 10 fractions).

2026-05-01addition (material)

Added several primary-site indications explicitly to the Coverage Rationale proven/medically necessary IMRT list, including unresectable hepatocellular carcinoma, unresectable intrahepatic cholangiocarcinoma, Hodgkin lymphoma, rectal cancer when treating inguinal nodes, limited-stage small cell lung cancer, retroperitoneal/intra-abdominal soft tissue sarcoma, and Stage I–II NSCLC undergoing hypofractionated RT up to 10 fractions.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (for New Jersey Only)

Policy CodePolicy CS064NJ.Q

Change TypeRevisedadditions and removals

Effective DateMay 1, 2026

Next Review Date

SourceLink

On This Page

Cervical cancer — ASTRO recommends IMRT to decrease acute and chronic toxicity for postoperative RT (strong); conditional recommendation for definitive RT; RCTs (PARCER) show IG-IMRT reduces GI toxicity vs 3D-CRT while maintaining tumor control.

Endometrial cancer — ASTRO and RCT/analyses support IMRT to reduce acute/late GI and hematologic toxicity for adjuvant pelvic RT; PORTEC3 secondary analysis favored IMRT for fewer severe AEs.

Esophageal cancer — NCCN: IMRT or proton may be used when critical organ sparing needed; trials show IMRT reduces irradiated heart/lung volumes; dose escalation to 61.6 Gy did not improve control vs 50.4 Gy in RCT.

Head & neck — ASTRO/NCCN recommend IMRT to spare critical structures; randomized and meta-analytic evidence shows reduced xerostomia and other toxicities with IMRT vs 3D-CRT.

DO-IMRT improved patient-reported swallowing vs standard IMRT in oropharyngeal/hypopharyngeal cancer.

IMRT associated with lower mandibular osteoradionecrosis risk versus 3D-CRT (systematic review).

Hepatocellular carcinoma: systematic review suggests IMRT yields comparable survival and low severe hepatic toxicity; ASTRO recommends EBRT (including IMRT/proton) for selected indications and dose-escalated regimens when appropriate.

HA-WBRT studies: HA-WBRT plus memantine preserves cognitive function vs WBRT plus memantine; hippocampal max doses reported ~12.6–17 Gy across studies.

NRG/CC001 and Brown et al. trials: HA-WBRT + memantine reduced cognitive failure with no significant difference in OS, intracranial PFS, or grade ≥3 toxicity vs WBRT + memantine.

NCCN: Recommends IMRT over 3D-CRT for stage III disease and prefers highly conformal RT with IGRT for early-stage when SABR not feasible; use IMRT in reirradiation to minimize toxicity.

Explain how IMRT will reduce cumulative normal-tissue dose compared with alternative techniques.

Billing Rule

Level 3 delivery justification when billing 77412

When billing CPT 77412, include documentation that clearly describes the clinical and technical circumstances that justify Level 3 (complex) delivery rather than Level 2, per the policy's coding clarification on 77412 vs 77407.

State whether multiple isocenters or active motion-management were required.
Describe imaging guidance and any additional complexity that differentiates level 3 from single-isocenter level 2 delivery (CPT 77407).

Documentation Required

Document guideline-based indications and target volumes for PMRT

For PMRT requests, document guideline-based indications and the planned target volumes: include nodal status (pN, ypN), T stage (pT, cT), details of any neoadjuvant therapy and pathologic response, and the planned treatment regions; when internal mammary node coverage is proposed, provide tumor-location, size, and nodal involvement rationale.

Specify chest wall or reconstructed-breast target and regional lymphatics (axillary, supra-/infraclavicular, internal mammary).
Document whether moderate hypofractionation or conventional fractionation is planned and reconstruction status.

Documentation Required

APBI patient selection documentation

For APBI prior authorization, supply documentation of patient selection per ASTRO criteria: patient age, tumor stage (Tis or T1), tumor size, nuclear grade (for DCIS), margin widths, and whether the lesion was screen-detected.

Record patient age (ASTRO suitable generally ≥50 years).
For DCIS, document screen-detection, low–intermediate grade, size ≤2.5 cm, and margins ≥3 mm.
If using NCCN-preferred IMRT/VMAT five-fraction schedule, note planned regimen.

Prior Authorization

IMRT/VMAT and image guidance when 3D-CRT insufficient

When requesting IMRT/VMAT because 3D-CRT cannot meet target or OAR goals, include the planning and dosimetric rationale and prior 3D constraints that demonstrate inability to meet goals; for PMRT with reconstruction or complex targets, document use of daily image guidance and DIBH if used.

Attach comparative plans or DVH data showing 3D-CRT failure to meet OAR constraints.
Document planned daily IGRT technique and whether DIBH is used to lower heart/lung dose.

Documentation Required

Radiation dosing and fractionation rationale

Document the planned fractionation and total dose for the course of radiation and provide a justification when deviating from preferred regimens (for example, when not using the NCCN/ASTRO-noted APBI five‑fraction schedule).

State whether moderate hypofractionation or conventional fractionation is planned and rationale for chosen schedule.
If proposing an alternative regimen, provide evidence or rationale supporting safety and efficacy for the patient.

Documentation Required

Technique selection based on OAR dose constraints

When electing IMRT over less conformal techniques, document why OAR dose constraints cannot be met with 3D techniques and include OAR DVH comparisons that justify IMRT based on dose‑volume benefits (e.g., parotid, mandible, heart, lung, hippocampus).

Provide DVH plots comparing target coverage and critical OAR metrics for IMRT versus alternative plans.
Reference the specific OAR constraint metrics that drove technique selection.

Documentation Required

Hippocampal avoidance planning and memantine use

For HA‑WBRT requests, include hippocampal contouring, planned hippocampal dose with maximums consistent with reported study ranges (~12.6–17 Gy), and documentation that memantine will be co‑administered per study protocols if applicable.

Provide hippocampal contours and hippocampal maximum and mean doses on plan DVH.
State memantine prescription and dosing plan consistent with trial protocols.

Documentation Required

Anatomic exclusion for HA-WBRT

Before prescribing HA‑WBRT, document that there are no metastases within the hippocampal‑avoidance region (typically within 5 mm of the hippocampus), and record the patient’s expected survival (≥4 months) and performance status as required by guidelines.

Include brain MRI or imaging demonstrating absence of lesions within 5 mm of hippocampi.
Document ECOG or Karnofsky performance status and estimated prognosis (≥4 months).

Documentation Required

Dose planning and OAR constraints

For dose‑escalation strategies (for example, IHC regimens with BED > 80.5 Gy), document the BED calculation, advanced planning/delivery techniques to be used, and image‑guidance strategies (daily CT IGRT, breath‑hold/gating) and demonstrate that OAR constraints can be met.

Provide BED calculation (specify α/β used) and supporting dosimetry.
List IGRT and motion‑management methods planned to safely deliver escalated dose.

Prior Authorization

Justify use of advanced modality

When requesting advanced modalities (IMRT/VMAT/PBRT) for dose escalation or OAR sparing, include a focused justification addressing tumor location, PTV size, proximity to critical structures, and treatment intent (curative vs palliative).

Describe how the chosen modality will improve target coverage or reduce dose to specific critical structures (heart, liver, duodenum, spinal cord).
State intended treatment intent and how modality selection supports that intent.

Denial Risk

High-dose RT in stage III NSCLC

Be aware that RTOG 0617 found 74 Gy with concurrent chemotherapy was associated with worse overall survival compared with 60 Gy; proposals for high‑dose RT in stage III NSCLC should include documentation justifying deviation from standard 60 Gy.

If proposing >60 Gy, provide rationale and supporting evidence that addresses the RTOG 0617 findings.
Include dosimetry demonstrating cardiac and pulmonary dose minimization measures.

Documentation Required

Use image guidance and motion management when indicated

Document use of image guidance and motion‑management when indicated for the site (examples in the policy include rectal cancer, SCLC, vulvar cancer, and pelvic nodal radiation) to verify localization and accommodate anatomic changes.

Specify IGRT frequency and type (e.g., cone‑beam CT, surface guidance) and any 4D or breath‑hold technique used.
Describe how image guidance will be used to adapt or verify treatment delivery.

Documentation Required

Consider IMRT for pelvic nodal radiation and reirradiation

For pelvic nodal radiation or reirradiation (prostate), document the clinical indication and planned nodal dose (AUA/ASTRO recommended range 45–52 Gy) and provide rationale for IMRT to minimize OAR exposure.

State planned pelvic nodal dose within 45–52 Gy and photon energy/field arrangement if relevant.
If reirradiation, include prior dose history and plan demonstrating cumulative constraints.

Note

Device/technology information is informational only

FDA device approvals listed in the policy are informational only; FDA approval does not by itself constitute coverage—consult payer coverage rules and preauthorization requirements separately.

Device/technology listings are provided for information and do not guarantee coverage.
Verify benefit plan, state, or contractual requirements for coverage decisions.

Denial Risk

Combined IMRT and PBRT in single plan not supported

The policy states there is no clinical evidence supporting combining IMRT and proton beam therapy in a single treatment plan; requests to combine IMRT and PBRT should be justified carefully as they may be unsupported and risk denial.

If proposing mixed‑modality single‑plan delivery, provide high‑level evidence or rationale addressing lack of supportive literature.
Be aware payers may consider such combined plans unproven and not medically necessary.

Documentation Required

Medical record must support medical necessity

Ensure the medical record fully supports medical necessity: include relevant history, physical exam, diagnostic test/procedure results, and make records legible and available upon request for review.

Maintain H&P, staging, pathology, imaging, and prior treatment documentation in the chart.
Expect that documentation may be requested during coverage review.

Prior Authorization

Documentation requirement for CPT 77412 billing

When billing CPT 77412, in prior‑authorization requests include clear documentation describing why level 3 (complex) delivery is required rather than level 2 (77407), per the policy's coding clarification.

Describe technical complexity such as multiple isocenters or active motion management and associated imaging needs.
Attach plan documentation that demonstrates the complexity claimed.

Documentation Required

Reference federal/state/contractual benefit terms

Before applying policy language, verify federal, state, or contractual benefit plan terms; these govern in the event of a conflict and may require different coverage obligations.

Check applicable benefit plan, state mandates, or federal rules that supersede standard policy statements.
Document any plan‑specific coverage exceptions when submitting authorization.

Documentation Required

Use independent clinical judgment

This policy is informational and should be used alongside the independent clinical judgment of a qualified healthcare provider when planning care; it does not replace individualized medical decision‑making.

Use the policy as guidance in conjunction with clinician expertise and patient‑specific factors.
Policy statements do not constitute medical advice or dictate the clinical plan.

Photon energy >= 6 MV; IMRT plan typically uses 5-9 fields

LS-SCLC recommended dose options45 Gy in 1.5-Gy twice-daily fractions OR 60-70 Gy in 1.8-2 Gy once-daily fractions

APBI patient selection (ASTRO) — age & tumor/marginAge >= 50; stage Tis or T1; surgical margins >= 2 mm

APBI DCIS specificsFor DCIS: screen-detected, low–intermediate nuclear grade, tumor size <= 2.5 cm, resection margins >= 3 mm

APBIAccelerated partial breast irradiation.

HA-WBRTHippocampal-avoidance whole-brain radiation therapy — WBRT technique that intentionally spares hippocampal regions to reduce cognitive decline.

DO-IMRTDysphagia-optimized intensity-modulated radiation therapy — IMRT planned to reduce dose to swallowing-related structures.

BEDBiologically effective dose — a radiobiologic calculation used to compare different fractionation regimens.

IGRTImage-guided radiation therapy — use of imaging during treatment to improve targeting accuracy.

InterQualA third-party clinical criteria tool UnitedHealthcare may use to assist in administering health benefits.

2026-05-01removal (material)

Removed language stating that compensator-based beam modulation is proven and medically necessary when combined with an IMRT indication.

2026-05-01revision (material)

Changed coverage phrasing for hippocampal-avoidance whole-brain radiation therapy (HA-WBRT) from 'proven and medically necessary' to 'considered proven and medically necessary' for up to 10 fractions when criteria are met.

2026-05-01documentation requirement (non-material)

Clarified medical-record documentation requirements: medical records must fully support medical necessity (including history, physical exam, and diagnostic test results), be legible, and be available upon request; federal/state/contractual requirements may affect coverage determinations.

2026-05-01coding (material)

Added CPT codes 77407 and 77412 to the Applicable Codes section and provided billing guidance distinguishing standard single-isocenter delivery (77407) from complex delivery (77412).

2026-05-01removal (material)

Removed CPT/HCPCS codes 77385, 77386, G6015, G6016, and G6017 from the applicable codes list.

2026-05-01clarification (material)

Added operational billing guidance: when CPT code 77412 is reported, documentation must clearly describe circumstances that justify Level 3 (complex) delivery rather than Level 2.

2026-05-01supporting material update (non-material)

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

2026-05-01archival (non-material)

Archived previous policy version CS064NJ.P.

Intensity-Modulated Radiation Therapy (for New Jersey Only)

Medical Necessity Criteria for IMRT (New Jersey Only)

Applicable Procedure and Billing Codes

Prior Authorization, Documentation & Billing Requirements

Numerical & Clinical Thresholds to Apply

Clinical & Administrative Background

Defined Terms

Other Policies to Review

Summary of Policy Changes